Could heart failure drugs boost oral Iron's power against anemia?

NCT ID NCT07708025

Completed Disease control Sponsor: Universidade do Porto Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at whether heart failure patients with iron deficiency anemia respond better to oral iron supplements when they are also taking a type of heart medication called SGLT2 inhibitors. Participants take oral iron for three to four months, then pause treatment while doctors monitor their blood. The goal is to see if the heart drug helps the body use iron more effectively to raise hemoglobin levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral iron supplementation (hydroxide polymaltose or ferrous sulfate)
What this could lead to: If successful, it could show that SGLT2i drugs improve how well oral iron works for heart failure patients with anemia, potentially simplifying treatment.
What could go wrong: This is a small, early-phase study with only 55 participants, and results may not apply to all heart failure patients. Oral iron absorption may still be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia heart failure iron deficiency anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEMIA HEART FAILURE

Contacts and locations

Show contact details

Locations

Unidade Local de Saúde São João

Porto, 4200-319, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.